Certainly, there was a concern that combining the two ADCs would lead to intolerable toxicities, but I think this study provides evidence that that’s not the case. The dose of SG, again, was reduced to 7.5 milligrams compared with the monotherapy dose of 10 milligrams per kilogram, so that helped. And also, the use of GCSF was mandated on this study, which prevented or mitigated the risk of neutropenic fever and neutropenic toxicity...
Certainly, there was a concern that combining the two ADCs would lead to intolerable toxicities, but I think this study provides evidence that that’s not the case. The dose of SG, again, was reduced to 7.5 milligrams compared with the monotherapy dose of 10 milligrams per kilogram, so that helped. And also, the use of GCSF was mandated on this study, which prevented or mitigated the risk of neutropenic fever and neutropenic toxicity. I mentioned three patients had neutropenia that was grade three. Those were all short-lived occurring in cycle one. And there was one DLT of neutropenic fever that was less than 24 hours. But nonetheless, patients were able to stay on therapy. And the toxicity of neuropathy was prevalent and actually did lead to discontinuation of inotuzumab-vedotin. But it didn’t seem to be beyond what is seen with inotuzumab plus pembrolizumab. So I think that the doublet has a lot of non-overlapping toxicity and can be mitigated with dose adjustments and careful monitoring of patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.